QI
SRNE

QS Investors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

QS Investors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$194K Sell
20,000
-200
-1% -$1.59K ﹤0.01% 1071
2021
Q1 		$168K Sell
20,200
-300
-1% -$3.17K ﹤0.01% 1133
2020
Q4 		$140K Hold
20,500
– – ﹤0.01% 1126
2020
Q3 		$229K Buy
+20,500
New +$188K ﹤0.01% 1030

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

QS Investors's SRNE Position: Q2 2021 in Review

QS Investors reduced its Sorrento Therapeutics, Inc. (SRNE) stake by 0.99% in Q2 2021, selling an estimated $1.59K and leaving 20,000 shares worth $194K. The position accounts for ﹤0.01% of the portfolio, ranked #1071.

QS Investors first reported a position in SRNE in Q3 2020 and has held it in 4 quarters since. The position peaked at $229K in Q3 2020. 212 funds tracked by Wall St. Rank hold SRNE as of Q2 2021.

  • QS Investors held 20,000 shares of Sorrento Therapeutics, Inc. worth $194K as of Q2 2021.
  • QS Investors sold 200 Sorrento Therapeutics, Inc. shares in Q2 2021, an estimated $1.59K.
  • Sorrento Therapeutics, Inc. made up ﹤0.01% of QS Investors's portfolio in Q2 2021, its #1071 holding.
  • QS Investors first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and has held it in 4 quarters since.
  • QS Investors's Sorrento Therapeutics, Inc. position peaked at $229K in Q3 2020.
  • 212 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.